Monoclonal Antibody
Adding Pertuzumab to Adjuvant Therapy Is Beneficial for Some Women with Early Breast Cancer
June 20, 2017Adding a second HER2-blocker to standard care therapy after surgery for HER2-positive breast cancer may be modestly beneficial for some women.
Checkpoint Inhibitors Appear Safe for Pediatric Cancer Patients
June 12, 2017The medications so far show little efficacy in children with cancer, but new studies may provide clues to how to change this, pediatric oncologist says.
Pembrolizumab Use With CRT Safe in Locally Advanced HNSCC
June 09, 2017Small study also showed that pembrolizumab does not significant impair radiation or chemotherapy dosing.
Adjuvant + Neoadjuvant Pembrolizumab Safe in Patients Undergoing HNSCC Surgery
June 09, 2017Study also provides evidence supporting an anti-tumor effect associated with a single preoperative dose of pembrolizumab.
Higher-Dose Adjuvant Ipilimumab More Toxic, Does Not Improve Recurrence-Free Survival
June 05, 2017Study of patients with resected high-risk melanoma reveals higher rates of treatment-related adverse events with 10 vs 3 mg/kg.
Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
April 20, 2017A significantly higher 5-year survival rate was seen in a small subset of patients with NSCLC treated with nivolumab.
Adjuvant Girentuximab Not Effective for Renal Cell Carcinoma
November 01, 2016Phase 2 studies have demonstrated that girentuximab possesses activity with a manageable safety profile for patients with clear cell renal cell carcinoma; therefore, in a phase 3 trial, researchers evaluated its efficacy and safety as adjuvant monotherapy.
Blinatumomab Improves Overall Survival in Acute Lymphoblastic Leukemia
June 23, 2016Overall survival for patients with acute lymphoblastic leukemia (ALL) was nearly doubled to 7.8 months from 4.0 months by treating patients with blinatumomab compared with standard of care.
Research Shows Potential for Breast Cancer Prevention in BRCA1-Driven Tumors
June 10, 2016The drug denosumab, which blocks a bone gene, may also prevent breast cancer caused by a BRCA1 mutation. This already approved drug could be available quickly, and would be the first drug for breast cancer prevention.
Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma
June 07, 2016Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.
Pembrolizumab Demonstrates Long-Term Survival in Advanced Melanoma
June 07, 2016At 3 years, 40% of patients with advanced melanoma treated with pembrolizumab are alive regardless of whether they had been treated with ipilimumab or not, follow-up results from the KEYNOTE-001 study reported at the ASCO 2016 Annual Meeting.
Daratumumab + Bortezomib/Dexamethasone: Reduced Risk of Disease Progression Seen in Relapsed or Refractory Multiple Myeloma
June 06, 2016Adding daratumumab to bortezomib and dexamethasone was associated with a 61% reduction in risk of disease progression in patients with relapsed or refractory multiple myeloma (RRMM), according to results of the phase 3 CASTOR study presented in a plenary session at the ASCO 2016 Annual Meeting.
Daratumumab Demonstrates Encouraging Efficacy in Patients With Pretreated or Refractory Multiple Myeloma
January 22, 2016Heavily pretreated and refractory patients with multiple myeloma had encouraging efficacy results with daratumumab monotherapy.
Experimental treatment shows early promise for advanced neuroblastoma in children
May 23, 2014Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody.
ONA Articles
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Eating and Exercising Towards Better Health in Cancer Survivors
- Oral Cancer Medications: New Paradigm Brings New Challenges
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |